SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA").
Malignant glioma has been a special challenge for patients and healthcare professionals for a long time, with limited treatment options including surgical resection, chemotherapy, and/or radiation therapy. The prognosis for the disease also remains poor, with median overall survival ("OS") varying between 12 - 14 months, a 5-year survival ranging from 4% to 5% and a nearly 100% relapse rate, representing a huge unmet medical need.
Developed on ImmVira's OvPENS new drug development platform, MVR-C5252 is designed specifically for the treatment of glioma by specific attenuation to achieve on-target malignant gliocyte killing while maintaining safety profile. MVR-C5252 is also the only oncolytic virus product targeting brain tumors that carries specific exogenous genes to promote the immune response of tumor microenvironment and achieve optimal anti-tumor activity. MVR-C5252 has obtained IND clearance from the U.S. FDA and is currently under preparation for Phase I clinical study.
FDA enacted the Orphan Drug Act to encourage and provide special incentives to pharmaceutical companies that undertake the responsibility of developing orphan drugs that target diseases affecting fewer than 200,000 people in the United States. The ODD status will further accelerate the clinical development and registration of MVR-C5252 in the United States, and will also allow MVR-C5252 to enjoy exclusive marketing and development rights and other benefits, such as protocol assistance from FDA, potential decreased wait-time for drug approval, discounts on certain fees, and eligibility for seven years of market exclusivity in the United States, etc.
Dr. Grace Guoying Zhou, ImmVira's Chairwoman and CEO, said, "ODD status granted by FDA to MVR-C5252 means a lot for glioma patients, and also demonstrated FDA's recognition for this product and company's clinical development and registration capability as well. ImmVira will continue to advance the clinical development of MVR-C5252 in both U.S. and China, promote the early launch of the candidate product to save more patients' lives."
ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors. Our advanced engineering created vectors that are highly oncolytic competent and as ideal exogenous gene delivery mechanisms. Leveraging intrinsic mechanism of action and tumor microenvironment modification, our products include replication capable oncolytic herpes simplex virus, and non-replicating exosome and tumor vaccine. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best-in-class mono and combo therapies on the OvPENS (Oncological vector+ Potent, Enabling, Novel & Safe) platform.
Our clinical stage and development stage pipelines target a wide range of solid tumors and hematologic malignancies, to be used as single agent or combination treatment solutions for cancer patients at different stages, unresponsive to immunotherapy or with rare tumors, by various administration methods including intratumoral, as well as first-in-class intravenous and intraperitoneal/pleural/vesical injections. The first three oncolytic virus products are currently undergoing five Phase I or Phase II clinical trials in both United States and China.
View original content to download multimedia:https://www.prnewswire.com/news-releases/immviras-brand-new-ohsv-product-mvr-c5252-targeting-malignant-glioma-obtained-fdas-orphan-drug-designation-301599610.html
- ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
- China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON
- CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
- CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022
- Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
- iNtRON Completes GLP-TOX Studies of BAL200
- InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer
- IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
- BRONCUS COMPLETED SURGERIES ON THE FIRST GROUP OF PATIENTS USING ITS InterVapor®, THE THERMAL VAPOR TREATMENT SYSTEM, AFTER APPROVED FOR MARKETING IN CHINA